Cash Flow Statement

Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Monte Rosa Therapeutics (GLUE) Change in Acquisitions & Divestments (2023)

Monte Rosa Therapeutics' Change in Acquisitions & Divestments history spans 1 years, with the latest figure at $45.6 million for Q1 2023.

For Q1 2023, Change in Acquisitions & Divestments changed N/A year-over-year to $45.6 million; the TTM value through Dec 2023 reached $45.6 million, changed N/A, while the annual FY2023 figure was $45.6 million, N/A changed from the prior year.
Change in Acquisitions & Divestments reached $45.6 million in Q1 2023 per GLUE's latest filing.
In the past five years, Change in Acquisitions & Divestments ranged from a high of $45.6 million in Q1 2023 to a low of $45.6 million in Q1 2023.